參考文獻 |
1. Zafar M, Sharif MI, Sharif MI, Kadry S, Bukhari SAC, Rauf HT: Skin Lesion Analysis and Cancer Detection Based on Machine/Deep Learning Techniques: A Comprehensive Survey. Life (Basel) 2023, 13(1).
2. Squamous Cell Carcinoma Of The Skin. Mayo Foundation for Medical Education and Research 2021.
3. Aggarwal P, Knabel P, Fleischer AB, Jr.: United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol 2021, 85(2):388-395.
4. Cencer TCR: CANCER REGISTRY ANNUAL REPORT, TAIWAN. 2020.
5. Ugurel S, Gutzmer R: Melanom. J Dtsch Dermatol Ges 2023.
6. Garutti M, Targato G, Buriolla S, Palmero L, Minisini AM, Puglisi F: CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells 2021, 10(6).
7. Carcamo S, Nguyen CB, Grossi E, Filipescu D, Alpsoy A, Dhiman A, Sun D, Narang S, Imig J, Martin TC et al: Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. Cell Rep 2022, 39(1):110637.
8. Cabrita R, Mitra S, Sanna A, Ekedahl H, Lovgren K, Olsson H, Ingvar C, Isaksson K, Lauss M, Carneiro A et al: The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers (Basel) 2020, 12(3).
9. Munoz-Couselo E, Garcia JS, Perez-Garcia JM, Cebrian VO, Castan JC: Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med 2015, 3(15):207.
10. Bhatia P, Friedlander P, Zakaria EA, Kandil E: Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med 2015, 3(2):24.
11. Shaughnessy M, Klebanov N, Tsao H: Clinical and therapeutic implications of melanoma genomics. Journal of Translational Genetics and Genomics 2018, 2:14.
12. Domingues B, Lopes JM, Soares P, Populo H: Melanoma treatment in review. Immunotargets Ther 2018, 7:35-49.
13. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, Group EGW: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23 Suppl 7:vii86-91.
14. Luke JJ, Schwartz GK: Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol 2013, 31(3):290-297.
15. Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 2017, 5(1):74.
16. Knight A, Karapetyan L, Kirkwood JM: Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel) 2023, 15(4).
17. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P et al: BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers (Basel) 2020, 12(7).
18. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
19. Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA: MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. Am J Clin Dermatol 2017, 18(6):745-754.
20. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A et al: The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010, 107(33):14903-14908.
21. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23(2):190-200.
22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287):427-430.
23. Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A et al: RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med 2019, 25(2):284-291.
24. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11(11):873-886.
25. Tangella LP, Clark ME, Gray ES: Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochim Biophys Acta Gen Subj 2021, 1865(1):129736.
26. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71(7):2750-2760.
27. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487(7408):505-509.
28. Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH et al: Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 2016, 22(9):1056-1061.
29. Gencler B, Gonul M: Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatol Res Pract 2016, 2016:5361569.
30. Boussemart L, Girault I, Malka-Mahieu H, Mateus C, Routier E, Rubington M, Kamsu-Kom N, Thomas M, Tomasic G, Agoussi S et al: Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. Cancer Res 2016, 76(6):1476-1484.
31. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P: Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 2020, 18(1):59.
32. Doyle LM, Wang MZ: Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells 2019, 8(7).
33. Nederveen JP, Warnier G, Di Carlo A, Nilsson MI, Tarnopolsky MA: Extracellular Vesicles and Exosomes: Insights From Exercise Science. Front Physiol 2020, 11:604274.
34. Lattmann E, Levesque MP: The Role of Extracellular Vesicles in Melanoma Progression. Cancers (Basel) 2022, 14(13).
35. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012, 18(6):883-891.
36. Biagioni A, Laurenzana A, Menicacci B, Peppicelli S, Andreucci E, Bianchini F, Guasti D, Paoli P, Serrati S, Mocali A et al: uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells. Cell Mol Life Sci 2021, 78(6):3057-3072.
37. Garcia-Silva S, Benito-Martin A, Nogues L, Hernandez-Barranco A, Mazariegos MS, Santos V, Hergueta-Redondo M, Ximenez-Embun P, Kataru RP, Lopez AA et al: Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat Cancer 2021, 2(12):1387-1405.
38. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S, Zacharias W, Hao H, McMasters KM: Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 2012, 7(10):e46874.
39. O‵Brien J, Hayder H, Zayed Y, Peng C: Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) 2018, 9:402.
40. Varrone F, Caputo E: The miRNAs Role in Melanoma and in Its Resistance to Therapy. Int J Mol Sci 2020, 21(3).
41. Luan W, Ding Y, Xi H, Ruan H, Lu F, Ma S, Wang J: Exosomal miR-106b-5p derived from melanoma cell promotes primary melanocytes epithelial-mesenchymal transition through targeting EphA4. J Exp Clin Cancer Res 2021, 40(1):107.
42. Bertoli G, Cava C, Diceglie C, Martelli C, Rizzo G, Piccotti F, Ottobrini L, Castiglioni I: MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration. Breast Cancer Res Treat 2017, 161(3):605-616.
43. Elkady MA, Doghish AS, Elshafei A, Elshafey MM: MicroRNA-567 inhibits cell proliferation and induces cell apoptosis in A549 NSCLC cells by regulating cyclin-dependent kinase 8. Saudi J Biol Sci 2021, 28(4):2581-2590.
44. Liu D, Zhang C, Li X, Zhang H, Pang Q, Wan A: MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma. EXCLI J 2018, 17:102-112.
45. Ma Y, Xue H, Wang W, Yuan Y, Liang F: The miR-567/RPL15/TGF-beta/Smad axis inhibits the stem-like properties and chemo-resistance of gastric cancer cells. Transl Cancer Res 2020, 9(5):3539-3549.
46. Han M, Hu J, Lu P, Cao H, Yu C, Li X, Qian X, Yang X, Yang Y, Han N et al: Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis 2020, 11(1):43.
47. Nguyen MT, Lin CH, Liu SM, Miyashita A, Ihn H, Lin H, Ng CH, Tsai JC, Chen MH, Tsai MS et al: miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. Neoplasia 2020, 22(12):789-799.
48. Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D: ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 2014, 9(3):e92444.
49. Dominska K, Kowalska K, Urbanek KA, Habrowska-Gorczynska DE, Ochedalski T, Piastowska Ciesielska AW: The Impact of Ang-(1-9) and Ang-(3-7) on the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes. Int J Mol Sci 2020, 21(17).
50. O‵Donnell JL, Joyce MR, Shannon AM, Harmey J, Geraghty J, Bouchier-Hayes D: Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006, 32(6):407-416.
51. Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci 2004, 117(Pt 20):4619-4628.
52. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C et al: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140(2):209-221.
53. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366(3):207-215.
54. Shelke GV, Lasser C, Gho YS, Lotvall J: Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum. J Extracell Vesicles 2014, 3.
55. Patel H, Mishra R, Yacoub N, Alanazi S, Kilroy MK, Garrett JT: IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers (Basel) 2021, 13(22).
56. Santos Apolonio J, Lima de Souza Goncalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF: Oncolytic virus therapy in cancer: A current review. World J Virol 2021, 10(5):229-255.
57. Rezaie J, Feghhi M, Etemadi T: A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal 2022, 20(1):145. |